A Phase I study to evaluate the safety and dosimetry of 68Ga-labelled OncoFAP derivatives in patients with solid tumors
Phase 1
Completed
- Conditions
- Patients with breast cancer, colorectal cancer, oesophageal cancer and pancreatic adenocarcinoma.
- Registration Number
- 2022-500902-16-00
- Lead Sponsor
- Philogen S.p.A., Philogen S.p.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ended
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Humanitas Research Hospital
🇮🇹Rozzano, Italy
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, Italy
National Cancer Institute
🇮🇹Milan, Italy
Ospedale San Raffaele S.r.l.
🇮🇹Milan, Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
🇮🇹Meldola, Italy
Humanitas Research Hospital🇮🇹Rozzano, ItalyMarcello RodariSite contact0282247544marcello.rodari@humanitas.it